Stefan Kasper1, Isabel Virchow2, Boris Hadaschik3, Jan Philipp Radtke3. 1. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland. stefan.kasper-virchow@uk-essen.de. 2. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland. 3. Klinik für Urologie, Kinderurologie und Uroonkologie, Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Deutschland.
Abstract
BACKGROUND: Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques that are becoming increasingly important in the diagnostic workup of cancer. Correct definition and interpretation of results are key challenges for both radiologists/specialists in nuclear medicine as well as for the treating clinician. Strong interdisciplinary communication is prerequisite to solve the upcoming complexity of retrieved information generated by hybrid imaging. OBJECTIVES: Different indications for hybrid medical imaging and review of current theranostic principles from the perspective of clinicians/clinical oncologists. MATERIALS AND METHODS: The GBA guidelines and recommendations retrieved from the corresponding German S3 guidelines for the use of PET imaging are summarized, followed by a review of innovative clinical trials that promote PET-based therapeutic strategies and radioligand therapies. RESULTS: Next generation PET/CT and PET/MRI imaging are being increasingly used for diagnostic purposes and follow-up staging in malignant tumors. Radioligand therapy may have the potential to be a further cornerstone in personalized antitumor therapy. CONCLUSIONS: Careful implementation of hybrid medical imaging can clearly improve the quality of the diagnosis in cancer patients and even increase the quality of care for cancer patients. Close interdisciplinary collaboration is essential to optimize therapeutic strategies for each patient.
BACKGROUND: Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques that are becoming increasingly important in the diagnostic workup of cancer. Correct definition and interpretation of results are key challenges for both radiologists/specialists in nuclear medicine as well as for the treating clinician. Strong interdisciplinary communication is prerequisite to solve the upcoming complexity of retrieved information generated by hybrid imaging. OBJECTIVES: Different indications for hybrid medical imaging and review of current theranostic principles from the perspective of clinicians/clinical oncologists. MATERIALS AND METHODS: The GBA guidelines and recommendations retrieved from the corresponding German S3 guidelines for the use of PET imaging are summarized, followed by a review of innovative clinical trials that promote PET-based therapeutic strategies and radioligand therapies. RESULTS: Next generation PET/CT and PET/MRI imaging are being increasingly used for diagnostic purposes and follow-up staging in malignant tumors. Radioligand therapy may have the potential to be a further cornerstone in personalized antitumor therapy. CONCLUSIONS: Careful implementation of hybrid medical imaging can clearly improve the quality of the diagnosis in cancerpatients and even increase the quality of care for cancerpatients. Close interdisciplinary collaboration is essential to optimize therapeutic strategies for each patient.
Authors: Bruce E Hillner; Barry A Siegel; Lucy Hanna; Anthony F Shields; Fenghai Duan; Ilana F Gareen; Bruce Quinn; R Edward Coleman Journal: J Nucl Med Date: 2012-03-23 Impact factor: 10.057
Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Rathan M Subramaniam; Anthony F Shields; Archana Sachedina; Lucy Hanna; Fenghai Duan; Barry A Siegel; Bruce E Hillner Journal: Oncologist Date: 2016-07-08
Authors: Matthias Eiber; Ken Herrmann; Jeremie Calais; Boris Hadaschik; Frederik L Giesel; Markus Hartenbach; Thomas Hope; Robert Reiter; Tobias Maurer; Wolfgang A Weber; Wolfgang P Fendler Journal: J Nucl Med Date: 2017-11-09 Impact factor: 10.057
Authors: H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler Journal: Urologe A Date: 2018-06 Impact factor: 0.639
Authors: Christian Meyer zum Büschenfelde; Ken Herrmann; Tibor Schuster; Hans Geinitz; Rupert Langer; Karin Becker; Katja Ott; Matthias Ebert; Frank Zimmermann; Helmut Friess; Markus Schwaiger; Christian Peschel; Florian Lordick; Bernd Joachim Krause Journal: J Nucl Med Date: 2011-07-15 Impact factor: 10.057
Authors: Ulrich Dührsen; Stefan Müller; Bernd Hertenstein; Henrike Thomssen; Jörg Kotzerke; Rolf Mesters; Wolfgang E Berdel; Christiane Franzius; Frank Kroschinsky; Matthias Weckesser; Dorothea Kofahl-Krause; Frank M Bengel; Jan Dürig; Johannes Matschke; Christine Schmitz; Thorsten Pöppel; Claudia Ose; Marcus Brinkmann; Paul La Rosée; Martin Freesmeyer; Andreas Hertel; Heinz-Gert Höffkes; Dirk Behringer; Gabriele Prange-Krex; Stefan Wilop; Thomas Krohn; Jens Holzinger; Martin Griesshammer; Aristoteles Giagounidis; Aruna Raghavachar; Georg Maschmeyer; Ingo Brink; Helga Bernhard; Uwe Haberkorn; Tobias Gaska; Lars Kurch; Daniëlle M E van Assema; Wolfram Klapper; Dieter Hoelzer; Lilli Geworski; Karl-Heinz Jöckel; André Scherag; Andreas Bockisch; Jan Rekowski; Andreas Hüttmann Journal: J Clin Oncol Date: 2018-05-11 Impact factor: 44.544
Authors: Louise Emmett; Reuben Tang; Rohan Nandurkar; George Hruby; Paul Roach; Jo Anne Watts; Thomas Cusick; Andrew Kneebone; Bao Ho; Lyn Chan; Pim J van Leeuwen; Matthijs J Scheltema; Andrew Nguyen; Charlotte Yin; Andrew Scott; Colin Tang; Michael McCarthy; Karen Fullard; Matthew Roberts; Roslyn Francis; Phillip Stricker Journal: J Nucl Med Date: 2019-11-01 Impact factor: 10.057